|
Age (years, mean ± sd)
|
60.0 ± 10.9
|
61.2 ± 13.8
|
0.1241
|
|
Women
|
281 (56.2)
|
289 (57.8)
|
0.6094
|
|
Medical history
|
|
Cerebrovascular disease
|
75 (15.0)
|
76 (15.2)
|
0.9296
|
|
Ischemic heart disease
|
115 (23.0)
|
102 (20.4)
|
0.3186
|
|
Other heart disease
|
112 (22.4)
|
101 (20.2)
|
0.3955
|
|
Rheumatoid arthritis
|
15 (3.0)
|
18 (3.6)
|
0.5954
|
|
Liver disease
|
68 (13.6)
|
68 (13.6)
|
1.0000
|
|
Kidney disease
|
20 (4.0)
|
25 (5.0)
|
0.4456
|
|
Hypertension
|
103 (20.6)
|
82 (16.4)
|
0.0872
|
|
Medication
|
|
Antihypertensive drugs
|
216 (43.2)
|
194 (38.8)
|
0.1572
|
|
ARB
|
110 (22.0)
|
112 (22.4)
|
0.8790
|
|
ACEI
|
19 (3.8)
|
20 (4.0)
|
0.8702
|
|
Beta blocker
|
35 (7.0)
|
33 (6.6)
|
0.8016
|
|
CCB
|
124 (24.8)
|
120 (24.0)
|
0.7684
|
|
Antihypertensive diuretic
|
4 (0.8)
|
2 (0.4)
|
0.4128
|
|
Other antihypertensive drugs
|
57 (11.4)
|
57 (11.4)
|
1.0000
|
|
Lipid-lowering drugs other than statins
|
|
Fibrate
|
13 (2.6)
|
15 (3.0)
|
0.7014
|
|
Bile acid sequestrant
|
4 (0.8)
|
4 (0.8)
|
1.0000
|
|
Nicotinic acid
|
7 (1.4)
|
5 (1.0)
|
0.5613
|
|
Cholesterol absorption inhibitor
|
1 (0.2)
|
0 (0.0)
|
0.3171
|
|
Other lipid-lowering drugs
|
16 (3.2)
|
13 (2.6)
|
0.5718
|
|
Antithrombotic drug
|
182 (36.4)
|
193 (38.6)
|
0.4724
|
|
Liver disease therapeutic
|
11 (2.2)
|
9 (1.8)
|
0.6514
|
|
Kidney disease therapeutic
|
4 (0.8)
|
6 (1.2)
|
0.5250
|
|
Proton pump inhibitor
|
92 (18.4)
|
79 (15.8)
|
0.2749
|
|
H2 blocker
|
60 (12.0)
|
70 (14.0)
|
0.3471
|
|
NSAID
|
129 (25.8)
|
131 (26.2)
|
0.8854
|
|
Non-thiazide diuretic
|
35 (7.0)
|
34 (6.8)
|
0.9007
|
|
Antiarrhythmic drug
|
45 (9.0)
|
46 (9.2)
|
0.9124
|
|
Laboratory parameters
|
|
Triglyceride (mg/dL, mean ± sd)
|
134.7 ± 65.4
|
134.4 ± 75.8
|
0.9494
|
|
Casual glucose (mg/dL, mean ± sd)
|
102.2 ± 10.0
|
101.8 ± 10.6
|
0.6250
|
